Scientific publications

Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma

Nov 1, 2019 | Magazine: Nature Medicine

Jun W Kim, Cesar P Marquez, Kaja Kostyrko, Amanda L Koehne, Kieren Marini, David R Simpson, Alex G Lee, Stanley G Leung, Leanne C Sayles, Joseph Shrager, Irene Ferrer, Luis Paz-Ares, Melanie Hayden Gephart, Silvestre Vicent, Jennifer R Cochran, E Alejandro Sweet-Cordero


Abstract

Proinflammatory cytokines in the tumor microenvironment can promote tumor growth, yet their value as therapeutic targets remains underexploited.

We validated the functional significance of the cardiotrophin-like cytokine factor 1 (CLCF1)-ciliary neurotrophic factor receptor (CNTFR) signaling axis in lung adenocarcinoma (LUAD) and generated a high-affinity soluble receptor (eCNTFR-Fc) that sequesters CLCF1, thereby inhibiting its oncogenic effects. eCNTFR-Fc inhibits tumor growth in multiple xenograft models and in an autochthonous, highly aggressive genetically engineered mouse model of LUAD, driven by activation of oncogenic Kras and loss of Trp53. Abrogation of CLCF1 through eCNTFR-Fc appears most effective in tumors driven by oncogenic KRAS.

We observed a correlation between the effectiveness of eCNTFR-Fc and the presence of KRAS mutations that retain the intrinsic capacity to hydrolyze guanosine triphosphate, suggesting that the mechanism of action may be related to altered guanosine triphosphate loading.

Overall, we nominate blockade of CLCF1-CNTFR signaling as a novel therapeutic opportunity for LUAD and potentially for other tumor types in which CLCF1 is present in the tumor microenvironment.

CITA DEL ARTÍCULO  Nat Med. 2019 Nov;25(11):1783-1795. doi: 10.1038/s41591-019-0612-2. Epub 2019 Nov 7

Our authors

Silvestre Vicent Cambra